文献速递先天性心脏病外科心外重症与机械循环支持

澳大利亚国家儿童心脏移植项目的成本效益分析

Cost-effectiveness of the National Pediatric Heart Transplantation Program in Australia.
PubMed 文献 · J Thorac Cardiovasc Surg · 2018-11-16

该研究回顾分析2003年1月至2015年6月澳大利亚国家转诊中心70例儿童心脏移植的医院成本,61例随访超过1年。结果显示原发移植平均费用278,480美元,随访第一年费用55,823美元,此后12,119美元;每获得一个质量调整生命年成本为29,161至44,481美元,长期存活者具有成本效益。

要点

  • 儿童心脏移植原发移植平均费用278,480美元,未随时间变化
  • 随访第一年费用55,823美元,此后年均12,119美元
  • 每质量调整生命年成本29,161至44,481美元,具成本效益

核心结论

  • 澳大利亚儿童心脏移植对长期存活者具有成本效益,即使需要心室辅助装置支持。

研究设计与样本

  • 回顾性分析2003年1月至2015年6月国家转诊中心70例儿童心脏移植的医院成本,61例随访超过1年。

主要发现

  • 原发心脏移植平均费用278,480美元(95%CI 219,282-337,679),未随时间变化。
  • 36%(22/61)儿童移植前需要机械循环支持。
  • 出院后第一年平均随访费用55,823美元(95%CI 47,631-64,015),此后年均12,119美元(95%CI 8,578-15,661)。
  • 每质量调整生命年成本敏感性分析为29,161至44,481美元。
  • 1年、3年、5年无治疗性排斥反应生存率分别为65.5%、63.2%、59.5%。

关键数值与推荐

  • 多变量分析显示住院费用较高与心室辅助装置和移植前住院时间相关。
  • 第一年随访费用增加与心内膜心肌活检和再入院时间相关。
  • 心内膜心肌活检占第一年随访费用的52%。

临床怎么用

  • 儿童心脏移植长期存活者具有成本效益,心室辅助装置支持者亦然。
  • 选择性进行监测性心内膜心肌活检可能节省成本。

局限性

  • 回顾性分析,样本量有限(61例随访超过1年),成本基于2016年美元。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Cost data for pediatric heart transplantation are scarce. We examined hospital cost of the national pediatric heart transplantation program in Australia and assessed factors associated with increased costs. METHODS: The hospital cost of all children who underwent heart transplantation at a national referral center between January 2003 and June 2015 and were followed more than 1 year was retrospectively analyzed. Lifetime follow-up costs were adjusted for quality of life and projected to life expectancy. All costs were reported in 2016 US dollars. RESULTS: Of 70 children who underwent heart transplantation in the study period, 61 were followed more than 1 year after transplantation (mean, 4.3 ± 2.5 years). Mean cost of primary heart transplantation was $278,480 (95% confidence interval, 219,282-337,679) and did not change over time. Pretransplant mechanical circulatory support was required in 36% (22/61) of children. On multivariable analysis, greater admission costs were associated with ventricular assist device and pretransplant length of stay. Mean annual follow-up cost after discharge was $55,823 (95% confidence interval, 47,631-64,015) in the first year and $12,119 (95% confidence interval, 8578-15,661) thereafter. Increased first-year follow-up costs were associated with endomyocardial biopsies and length of readmissions. Cost per quality-adjusted life-year gained varied from $29,161 to $44,481 on sensitivity analysis. Freedom from treated rejections was 65.5% at 1 year, 63.2% at 3 years, and 59.5% at 5 years. Endomyocardial biopsies contributed to 52% of first-year follow-up costs. CONCLUSIONS: Primary pediatric heart transplantation in Australia is cost-effective for long-term survivors, even for those supported by ventricular assist device. Surveillance endomyocardial biopsy was a major contributor to post-transplantation costs. Selective targeting of surveillance biopsies may be cost-saving.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Ye XT, Parker A, Brink J, et al. Cost-effectiveness of the National Pediatric Heart Transplantation Program in Australia. J Thorac Cardiovasc Surg. 2018. PMID: 30578063. doi:10.1016/j.jtcvs.2018.11.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。